echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > 2021 AACR: Bayer plans to announce iNHL Phase III clinical data and its...

    2021 AACR: Bayer plans to announce iNHL Phase III clinical data and its...

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compileriver

    On April 6, according to foreign media reports, Bayer plans to present its new research in the field of oncology at the 2021 Virtual American Association for Cancer Research (AACR) annual meeting.


    In 2017, based on the results of a single-arm, multi-center, phase II clinical trial of CHRONOS-1, Aliqopa was approved for the treatment of adult patients with recurrent follicular lymphoma (FL) who had received at least two systemic treatments before.


    At this meeting, Bayer will also present relevant data on biomarker-driven therapy.


    Vitrakvi is approved for the treatment of adult and pediatric solid tumor patients who carry NTRK fusion gene but have no known acquired mutations, metastasis or surgical resection may lead to serious diseases, and who do not have satisfactory alternative treatments or progress after treatment.


    This time, the company will also report on the prostate cancer research of NUBEQA® (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).


    NUBEQA is an androgen receptor inhibitor (ARi) with a unique chemical structure that can competitively inhibit androgen binding, AR nuclear translocation and AR-mediated transcription.


    Bayer will also release the latest data on its differentiated early-stage pipelines in other key areas, including precision molecular oncology and immuno-oncology.


    Reference source: Bayer to Present New Clinical Data in Indolent non-Hodgkin's Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021

    Reference source: Bayer to Present New Clinical Data in Indolent non-Hodgkin's Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.